MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/j.1523-1755.2005.67139.x

Медицинская библиотека · Kidney international · 2005

Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

Moe Sharon M, Chertow Glenn M, Coburn Jack W, Quarles L Darryl, Goodman William G, Block Geoffrey A, Drüeke Tilman B, Cunningham John, Sherrard Donald J, McCary Laura C, Olson Kurt A, Turner Stewart A, Martin Kevin J

Клиническое исследованиеСтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-K/DOQItrade mark) has established guidelines for treatment of secondary hyperparathyroidism (HPT). The ability of cinacalcet HCl (Sensipartrade mark) treatment to improve achievement of target levels of parathyroid hormone (PTH), calcium, phosphorus, and calcium-phosphorus product (Ca x P) was investigated in subjects on dialysis with secondary HPT.

METHODS

Data were combined from three placebo-controlled, double-blind, 26-week studies with similar design that randomized 1136 subjects on dialysis to receive traditional therapy plus cinacalcet or placebo. Oral cinacalcet was titrated from 30 to 180 mg/day. Achievement of K/DOQI goals was determined for each treatment group overall and for subgroups defined by baseline intact PTH (iPTH) and Ca x P levels.

RESULTS

Cinacalcet-treated subjects were more likely to achieve a mean iPTH </=300 pg/mL (31.8 pmol/L) than were control subjects on traditional therapy (56% vs. 10%, P < 0.001). Cinacalcet-treated subjects were more likely to achieve concentrations of serum calcium within 8.4 to 9.5 mg/dL (2.10-2.37 mmol/L) and serum phosphorus within 3.5 to 5.5 mg/dL (1.13-1.78 mmol/L) than were control subjects (49% vs. 24% and 46% vs. 33%, P < 0.001 for each). Cinacalcet also improved achievement of Ca x P < 55 mg(2)/dL(2) (4.44 mmol(2)/L(2)) and concurrent achievement of Ca x P < 55 mg(2)/dL(2) (4.44 mmol(2)/L(2)) and iPTH </=300 pg/mL (31.8 pmol/L) (65% vs. 36% and 41% vs. 6%, P < 0.001 for each).

CONCLUSION

In subjects on dialysis with secondary HPT, cinacalcet facilitates achievement of the K/DOQI-recommended targets for PTH, calcium, phosphorus, and Ca x P.

Для цитирования: Moe Sharon M, Chertow Glenn M, Coburn Jack W, Quarles L Darryl, Goodman William G, Block Geoffrey A, Drüeke Tilman B, Cunningham John, Sherrard Donald J, McCary Laura C, Olson Kurt A, Turner Stewart A, Martin Kevin J. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.. Kidney international. 2005. DOI: 10.1111/j.1523-1755.2005.67139.x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.